Neonatal alloimmune thrombocytopenia: two different neonatal manifestations of the same disease

Authors

  • Miguel P. Pereira Department of Pediatrics and Neonatology, CUF Descobertas Hospital, Lisbon, Portugal http://orcid.org/0000-0002-3783-6114
  • Marta Pinto Department of Obstetrics and Gynecology, CHUC, Coimbra, Portugal
  • Mafalda Lucas Department of Pediatrics and Neonatology, CUF Descobertas Hospital, Lisbon, Portugal
  • Ana P. Domingues Department of Obstetrics and Gynecology, CUF Descobertas Hospital, Lisbon, Portugal
  • Cristina Matos Department of Pediatrics and Neonatology, CUF Descobertas Hospital, Lisbon, Portugal
  • Jorge Lima 3Department of Obstetrics and Gynecology, CUF Descobertas Hospital, Lisbon, Portugal 4Comprehensive Health Research Centre, CEDOC, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20212683

Keywords:

Neonatal alloimmune thrombocytopenia, Neonatal stroke, Prenatal screening, Antenatal management

Abstract

Fetal and neonatal alloimmune thrombocytopenia is a rare disorder in which maternal alloantibodies cross the placenta and cause fetal thrombocytopenia. Most cases are mild but can be potentially fatal if there is an intracranial haemorrhage. Usually, the mother is asymptomatic during pregnancy and no screening is routinely recommended unless there is obstetric or family history. After birth, prompt identification is crucial so that the newborn is closely monitored and treatment is given, if needed, to prevent serious complications. In this article we present two clinical cases of fetal and neonatal alloimmune thrombocytopenia in first-born children, after uneventful pregnancies, with different outcomes and discuss the obstetric management and follow-up in future pregnancies.

References

Liu Z, Bussel JB, Lakkaraja M, Ferrer-Marin F, Ghevaert C, Feldman HA, et al. Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies. Blood. 2015;126(10):1234-6.

Bussel J, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337:22-6.

Knight M, Pierce M, Allen D, Kurinczuk JJ, Spark P, Roberts DJ, et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol. 2011;152(4):460-8.

Kamphuis M, Paridaans NP, Porcelijn L, Lopriore E, Oepkes D. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014;133(4):715-21.

Caraciolo JF. Neonatal immune-mediated thrombocytopenia. Available at: https://www.uptodate.com. Accessed on 05 May 2020.

Delbos F, Bertrand G, Croisille L, Ansart-Pirenne H, Bierling P, Kaplan C. Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage. Transfusion. 2016;56(1):59-66.

Tiller H, Kamphuis MM, Flodmark O, Papadogiannakis N, David AL, Sainio S, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013;3(3):e002490.

Zdravic D, Yougbare I, Vadasz B, Li C, Marshall AH, Pingguo Chen, et al. Fetal and neonatal alloimmune thrombocytopenia. Sem Fetal Neonat Med. 2016:21(1):19-27.

Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019;185(3):549-62.

Allen D, Verjee S, Rees S, Murphy MF, Roberts DJ. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood. 2007;109(1):388-9.

Bakchoul T, Sachs UJ, Wittekindt B, Sclösser R, Bein G, Santoso S. Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets. Pediatr Blood Cancer. 2008;50:1293-4.

Peterson J, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013;161(1):3-14.

Bussel J, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203(2):135.

Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica. 2008;93(6):870-7.

Paidas MJ. UpToDate. Fetal and neonatal alloimmune thrombocytopenia: Parental evaluation and pregnancy management. Available at: https://www.uptodate.com. Accessed on 05 May 2020.

Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol. 2011;118(5):1157-63.

Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011;(5):CD004226.

Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A, et al. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT). BJOG. 2019;126(10):173-85.

Downloads

Published

2021-06-28

Issue

Section

Case Reports